文献速递青光眼

EYEMATE-SC试验:用于遥测眼压测量的脉络膜上腔传感器12个月安全性、性能和准确性

EYEMATE-SC Trial: Twelve-Month Safety, Performance, and Accuracy of a Suprachoroidal Sensor for Telemetric Measurement of Intraocular Pressure.
PubMed 文献 · Ophthalmology · 2022-10-03

这项前瞻性、多中心、开放标签、单臂介入临床试验在24例接受非穿透性青光眼手术的原发性开角型青光眼患者中植入EYEMATE-SC传感器,评估12个月安全性及与Goldmann压平眼压计(GAT)的一致性。所有眼均成功植入,无设备移位或严重设备相关并发症;总体平均差异0.8 mmHg(95%CI LoA -5.1至6.7 mmHg),术后3个月起平均差异-0.2 mmHg(95%CI LoA -4.6至4.2 mmHg),100%测量在GAT±5 mmHg内。

要点

  • 24眼中15眼行小梁切开术、9眼行深层巩膜切除术,均成功植入传感器,无术中困难报告。
  • 12个月随访内无设备移位、脱位或严重设备相关并发症记录。
  • 术后3个月至随访结束共264次测量,EYEMATE-SC与GAT平均差异-0.2 mmHg,100%在±5 mmHg内。

核心结论

  • EYEMATE-SC传感器在12个月内安全且耐受良好,并允许准确、连续的眼压监测。

研究设计与样本

  • 前瞻性、多中心、开放标签、单臂介入临床试验,纳入24例原发性开角型青光眼患者的24眼,均计划接受非穿透性青光眼手术(小梁切开术或深层巩膜切除术)。

主要发现

  • 15眼行小梁切开术,9眼行深层巩膜切除术,所有眼均成功植入传感器,无术中困难报告。
  • 12个月随访内无设备移位、脱位或严重设备相关并发症记录。
  • 共536次EYEMATE-SC测量纳入与GAT的一致性分析,总体平均差异0.8 mmHg(95%CI LoA -5.1至6.7 mmHg)。
  • 术后3个月至随访结束共264次EYEMATE-SC测量,平均差异-0.2 mmHg(95%CI LoA -4.6至4.2 mmHg),100%测量在GAT±5 mmHg内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Measuring and controlling intraocular pressure (IOP) provide the foundation for glaucoma treatment. Self-tonometry has been proposed as an alternative to measure IOP throughout the entire day better. The novel EYEMATE-SC sensor (Implandata) is implanted in the suprachoroidal space to enable contactless continual IOP monitoring. The aim of the present study was to investigate the 1-year safety, performance, and accuracy of the EYEMATE-SC in patients with primary open-angle glaucoma undergoing simultaneous nonpenetrating glaucoma surgery (NPGS). DESIGN: Prospective, multicenter, open-label, single-arm, interventional clinical trial. PARTICIPANTS: Twenty-four eyes of 24 patients with primary open-angle glaucoma who were due to undergo NPGS (canaloplasty or deep sclerectomy). METHODS: An EYEMATE-SC sensor was implanted during NPGS. Goldmann applanation tonometry (GAT) measurements were compared with the sensors' IOP measurements at all postoperative visits through 12 months. MAIN OUTCOME MEASURES: Device position and adverse events. RESULTS: Fifteen eyes underwent canaloplasty, and 9 underwent deep sclerectomy. Successful implantation of the sensor was achieved in all eyes with no reported intraoperative difficulties. Through the 12-month follow-up, no device migration, dislocation, or serious device-related complications were recorded. A total of 536 EYEMATE-SC measurements were pairwise included in the IOP agreement analysis. The overall mean difference between GAT and EYEMATE-SC measurements was 0.8 mmHg (95% confidence interval [CI] of the limits of agreement [LoA], -5.1 to 6.7 mmHg). The agreement gradually improved, and from 3 months after surgery until the end of the follow-up, the mean difference was -0.2 mmHg (95% CI of LoA, -4.6 to 4.2 mmHg) over a total of 264 EYEMATE-SC measurements, and 100% of measurements were within ±5 mmHg of GAT. CONCLUSIONS: The EYEMATE-SC sensor was safe and well tolerated through 12 months. Moreover, it allowed accurate, continuous IOP monitoring. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Szurman P, Gillmann K, Seuthe AM, et al. EYEMATE-SC Trial: Twelve-Month Safety, Performance, and Accuracy of a Suprachoroidal Sensor for Telemetric Measurement of Intraocular Pressure. Ophthalmology. 2022. PMID: 36202141. doi:10.1016/j.ophtha.2022.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。